[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-377435-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-377435-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-outpost-against-cancer-universal-cancer-only-markers","The outpost against cancer - universal cancer only markers","","Cancer is the leading cause of death worldwide, and effective early-detection biomarkers remain scarce for most cancer types. DNA methylation is a major focus because it often occurs before other detectable genetic alterations. Using a guide positioning sequencing approach for DNA methylation, universal cancer only markers (UCOMs) emerged as strong candidates for accurate early detection. UCOMs show clinically meaningful value despite limitations of current biomarkers in sensitivity and specificity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-outpost-against-cancer-universal-cancer-only-markers/377435/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-outpost-against-cancer-universal-cancer-only-markers/377435.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are new cancer biomarkers urgently needed?","Question",{"text":63,"@type":64},"Cancer remains a major global health threat with high incidence and mortality. Current early detection options face limitations, so improved biomarkers are required to enhance prognosis and survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What makes DNA methylation a promising target for early cancer detection?",{"text":68,"@type":64},"DNA methylation usually occurs before other detectable genetic changes, making it suitable for identifying early disease signals.",{"name":70,"@type":61,"acceptedAnswer":71},"What are universal cancer only markers (UCOMs) and how are they validated?",{"text":72,"@type":64},"UCOMs are candidate biomarkers derived from common features of cancer using DNA methylation sequencing. Their clinical potential is supported by validation across multiple cancers including lung, cervical, endometrial, and urothelial types.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},377435,1790304232,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Biol Med 2023. doi: 10.20892/j.issn.2095-3941.2023.0313  \nMINI REVIEW  \nThe outpost against cancer: universal cancer only markers  \nChengchen Qian1, Xiaolong Zou2, Wei Li1,3, Yinshan Li4, Wenqiang Yu5  \n1Shanghai Epiprobe Biotechnology Co., Ltd, Shanghai 200233, China; 2 Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China; 3Shandong Epiprobe Medical Laboratory Co., Ltd, Heze 274108, China; 4 People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan 750002, China; 5Shanghai Public Health Clinical Center & Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China  \n\n| ABSTRACT | Cancer is the leading cause of death worldwide. Early detection of cancer can lower the mortality of all types of cancer; however, effective early-detection biomarkers are lacking for most types of cancers. DNA methylation has always been a major target of interest because DNA methylation usually occurs before other detectable genetic changes. While investigating the common features of cancer using a novel guide positioning sequencing for DNA methylation, a series of universal cancer only markers (UCOMs) have emerged as strong candidates for effective and accurate early detection of cancer. While the clinical value of current cancer biomarkers is diminished by low sensitivity and/or low specificity, the unique characteristics of UCOMs ensure clinically meaningful |\n| --- | --- |\n| KEYWORDS | results. Validation of the clinical potential of UCOMs in lung, cervical, endometrial, and urothelial cancers further supports the application of UCOMs in multiple cancer types and various clinical scenarios. In fact, the applications of UCOMs are currently under active investigation with further evaluation in the early detection of cancer, auxiliary diagnosis, treatment efficacy, and recurrence monitoring. The molecular mechanisms by which UCOMs detect cancers are the next important topics to be investigated. The application of UCOMs in real-world scenarios also requires implementation and refinement.\u003Cbr>Cancer detection; cancer screening; DNA methylation; cancer epigenetics; cancer biomarkers |\n\nWhy we urgently need new biomarkers?  \nAfter combatting cancer for over a century, cancer is still the most lethal biological threat to mankind. Cancer remains a global health concern with 19.3 million new cases and nearly 10 million deaths estimated in 20201. In 2020 an estimated 4.6 million new cases of cancer were diagnosed in China, accounting for 23.7% of new cancer cases globally according to GLOBOCAN 1. Furthermore, approximately 3 million deaths were attributed to cancer in China in 2020, which were 30% of global cancer-related deaths 1. These statistics indicated that  \nCorrespondence to: Yinshan Li and Wenqiang Yu  \nEmail: [liyinshan@nxrmyy.com and wenqiangyu@fudan.edu.cn](liyinshan@nxrmyy.com and wenqiangyu@fudan.edu.cn)  \nORCID ID: [https://orcid.org/0009-0005-3340-6802](https://orcid.org/0009-0005-3340-6802) and  \n[https://orcid.org/0000-0001-9920-1133](https://orcid.org/0000-0001-9920-1133)  \nReceived August 22, 2023; accepted October 12, 2023; published online November 28, 2023.  \nAvailable [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2023 Cancer Biology & Medicine. Creative Commons Attribution-NonCommercial 4.0 International License  \nChina ranks first in the incidence and mortality rate of cancer. Moreover, the 5-year cancer survival rate is 40.5%, which is 1.5 times lower than the 5-year survival rate in the United States2,3. The comparatively lower survival and higher mortality rates in China than in countries with higher human development indexes suggest that an efficient and cost-effective cancer prevention and surveillance system is urgently needed. Early detection of cancer is one of the most c","cbCaimmGYhxdVMGw","https://ap.wps.com/l/cbCaimmGYhxdVMGw","pdf",484248,"English","# Abstract\n# Why we urgently need new biomarkers?\n# Current early detection strategies\n## Biomarker categories","[{\"question\":\"Why are new cancer biomarkers urgently needed?\",\"answer\":\"Cancer remains a major global health threat with high incidence and mortality. Current early detection options face limitations, so improved biomarkers are required to enhance prognosis and survival.\"},{\"question\":\"What makes DNA methylation a promising target for early cancer detection?\",\"answer\":\"DNA methylation usually occurs before other detectable genetic changes, making it suitable for identifying early disease signals.\"},{\"question\":\"What are universal cancer only markers (UCOMs) and how are they validated?\",\"answer\":\"UCOMs are candidate biomarkers derived from common features of cancer using DNA methylation sequencing. Their clinical potential is supported by validation across multiple cancers including lung, cervical, endometrial, and urothelial types.\"}]","The outpost against cancer - universal cancer only markers | PDF",1790224941,25]